Key result
CHIP linked to ~25% higher risk of incident heart failure.
Why the study?
Age-related clonal hematopoiesis of indeterminate potential (CHIP) is associated with cardiovascular events including recurrent heart failure, but its association with incident heart failure is unclear.
Does clonal hematopoiesis of indeterminate potential (CHIP) increase the risk of incident heart failure in individuals without prevalent HF?
Cohort (n=56,597)
Yes
Does clonal hematopoiesis of indeterminate potential (CHIP) increase the risk of incident heart failure in individuals without prevalent HF?
Answers are grounded in this paper and cite their sources.
Clonal hematopoiesis of indeterminate potential (CHIP), particularly mutations in ASXL1, TET2, and JAK2, is independently associated with an increased risk of incident heart failure.
Age-related clonal hematopoiesis of indeterminate potential (CHIP), defined as clonally expanded leukemogenic mutations (particularly in DNMT3A , TET2 , ASXL1 , JAK2 ) in asymptomatic individuals, is associated with cardiovascular events, including recurrent heart failure (HF). We sought to evaluate whether CHIP is associated with incident HF. We obtained CHIP status from whole exome or genome sequencing of blood DNA in participants without prevalent HF or hematologic malignancy from five cohorts. Cox proportional hazards models were performed within each cohort, adjusting for demographic and clinical risk factors, followed by fixed-effect meta-analyses. Large CHIP clones (defined as variant allele frequency >10%), HF with or without baseline coronary heart disease (CHD), and left ventricular ejection fraction (LVEF) were evaluated in secondary analyses. Of 56,597 individuals (59% female, mean age 58 years at baseline), 3,406 (6%) had CHIP, and 4,694 developed HF (8.3%) over up to 20 years of follow up. CHIP was prospectively associated with a 25% increased risk of HF in meta-analysis (HR= 1.25, 95% CI 1.13, 1.38) with consistent associations across cohorts. ASXL1 , TET2 , and JAK2 mutations were each associated with an increased risk of HF, whereas DNMT3A mutations were not associated with HF. Secondary analyses suggested large CHIP was associated with a greater risk of HF (HR=1.29, 95% CI 1.15, 1.44), and the associations for CHIP on HF with and without prior CHD were homogenous. ASXL1 mutations were associated with reduced LVEF. CHIP, particularly mutations in ASXL1 , TET2 , and JAK2, represents a new risk factor for HF. Clonal hematopoiesis of indeterminate potential (CHIP) in asymptomatic individuals is associated with cardiovascular events, including recurrent heart failure (HF). We obtained CHIP status from five cohorts and evaluated whether CHIP was associated with incident HF. Of 56,597 individuals, 3,406 had CHIP, and 4,694 developed HF over 20 years of follow up. CHIP was associated with a 25% increased risk of HF. ASXL1 , TET2 , and JAK2 were each associated with an increased risk of HF. Large CHIP was suggested to have a greater risk of HF. CHIP, particularly mutations in ASXL1 , TET2 , and JAK2 , represents a new risk factor for HF.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2021) conducted a cohort in Incident Heart Failure (n=56,597). Clonal hematopoiesis of indeterminate potential (CHIP) vs. No CHIP was evaluated on Incident heart failure (HR 1.25, 95% CI 1.13-1.38). Clonal hematopoiesis of indeterminate potential (CHIP) was associated with a 25% increased risk of incident heart failure over up to 20 years of follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: